Probiotics Target Inflammaging in HIV Patients on Antiretroviral Therapy
A completed trial tested whether probiotic and prebiotic supplementation could reduce premature aging-related inflammation in people living with HIV.
Summary
People living with HIV who are on antiretroviral therapy often experience accelerated biological aging, partly driven by chronic low-grade inflammation known as inflammaging. This completed clinical trial, sponsored by AB Biotics, SA, investigated whether adding a probiotic and prebiotic supplement to standard antiretroviral treatment could slow or reverse this process. The gut microbiome plays a key role in immune regulation, and dysbiosis is common in HIV patients even when viral load is suppressed. By targeting the gut-immune axis, researchers hoped to reduce systemic inflammation and its downstream effects on aging. While full results are not yet publicly available, the trial's completion marks an important step toward understanding whether accessible, low-risk interventions like probiotics can meaningfully address one of the most pressing complications of long-term HIV management.
Detailed Summary
Chronic HIV infection, even when well-controlled with modern antiretroviral therapy, is associated with premature biological aging. Patients often develop age-related conditions — cardiovascular disease, cognitive decline, and metabolic dysfunction — decades earlier than the general population. A key driver is persistent systemic inflammation, a phenomenon researchers call inflammaging, fueled in part by ongoing immune activation and gut microbiome disruption.
This completed clinical trial, registered on ClinicalTrials.gov (NCT03542786) and sponsored by AB Biotics, SA, sought to address this problem through a targeted probiotic and prebiotic intervention. The trial enrolled individuals living with HIV who were already receiving antiretroviral treatment and randomized them to receive either a probiotic-prebiotic combination or placebo in addition to their standard care. The study was categorized as Phase NA, suggesting it was exploratory or pilot in nature.
The core hypothesis is that modulating the gut microbiome can reduce immune activation and systemic inflammation in HIV-positive individuals, thereby slowing the accelerated aging trajectory commonly observed in this population. The gut-immune axis is increasingly recognized as central to inflammaging across multiple disease contexts, making probiotics a compelling and low-cost therapeutic candidate.
While detailed results from this trial have not yet been published or made publicly accessible, its completion is a meaningful milestone. Confirming even modest anti-inflammatory effects from probiotic supplementation in this population could open the door to widely deployable, low-risk adjunct therapies for HIV care.
For clinicians managing aging HIV-positive patients, the gut microbiome represents an underutilized therapeutic target. Pending full publication of results, this trial adds to a growing body of evidence suggesting that nutritional and microbiome-based strategies deserve serious consideration alongside standard antiretroviral regimens.
Key Findings
- Trial tested probiotics and prebiotics as adjuncts to antiretroviral therapy to counter HIV-associated premature aging.
- Inflammaging — chronic low-grade inflammation — is a primary aging driver in HIV patients even with suppressed viral loads.
- Gut microbiome modulation may reduce systemic immune activation and slow biological aging in HIV-positive individuals.
- Trial is completed but full results are not yet publicly available; detailed findings are pending publication.
- Low-risk probiotic interventions could become accessible adjunct therapies for long-term HIV management.
Methodology
This was a randomized, placebo-controlled clinical trial (NCT03542786) evaluating a probiotic and prebiotic intervention added to existing antiretroviral therapy in people living with HIV. The trial was sponsored by AB Biotics, SA and is listed as completed on ClinicalTrials.gov. Phase was listed as NA, suggesting exploratory or pilot design; full protocol details and sample size are not disclosed in the available abstract.
Study Limitations
This summary is based on the abstract and ClinicalTrials.gov registration only, as the full study data and results are not publicly available. Key details including sample size, specific probiotic strains used, primary outcome measures, and results cannot be assessed. The exploratory phase designation limits the ability to draw definitive clinical conclusions from this trial alone.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.